172 related articles for article (PubMed ID: 29506310)
1. First Line Sorafenib Treatment for Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
Kocsis J; Szekanecz É; Bassam A; Uhlyarik A; Pápai Z; Rubovszky G; Mezősi E; Rucz K; Garai I; Nagy E; Uray I; Horváth Z
Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):240-246. PubMed ID: 29506310
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
[TBL] [Abstract][Full Text] [Related]
4. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
[No Abstract] [Full Text] [Related]
5. Sorafenib in metastatic thyroid cancer.
Capdevila J; Iglesias L; Halperin I; Segura A; Martínez-Trufero J; Vaz MÁ; Corral J; Obiols G; Grande E; Grau JJ; Tabernero J
Endocr Relat Cancer; 2012 Apr; 19(2):209-16. PubMed ID: 22285864
[TBL] [Abstract][Full Text] [Related]
6. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib in metastatic thyroid cancer: a systematic review.
Thomas L; Lai SY; Dong W; Feng L; Dadu R; Regone RM; Cabanillas ME
Oncologist; 2014 Mar; 19(3):251-8. PubMed ID: 24563075
[TBL] [Abstract][Full Text] [Related]
8. SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.
Uchino K; Komoda M; Tomomatsu J; Okamoto T; Horiuchi K; Tsuji A; Ito Y; Todo T; Rito K; Takahashi S
Endocr Pract; 2017 Feb; 23(2):149-156. PubMed ID: 27819766
[TBL] [Abstract][Full Text] [Related]
9. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
Krajewska J; Olczyk T; Jarzab B
Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165
[TBL] [Abstract][Full Text] [Related]
10. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial.
Chen J; Ji Q; Bai C; Zheng X; Zhang Y; Shi F; Li X; Tang P; Xu Z; Huang R; Huang T; Pan Y; Fan S; Zhou J; Su W
Thyroid; 2020 Sep; 30(9):1245-1253. PubMed ID: 32075524
[No Abstract] [Full Text] [Related]
11. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
Chougnet CN; Borget I; Leboulleux S; de la Fouchardiere C; Bonichon F; Criniere L; Niccoli P; Bardet S; Schneegans O; Zanetta S; Schvartz C; Drui D; Chauffert B; Rohmer V; Schlumberger M
Thyroid; 2015 Apr; 25(4):386-91. PubMed ID: 25627619
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and toxicity of sorafenib in the treatment of advanced medullary thyroid carcinoma: A systematic review and meta-analysis.
Vuong HG; Ho ATN; Tran TTK; Capdevila J; Benekli M; Nakazawa T; Katoh R; Kondo T
Head Neck; 2019 Aug; 41(8):2823-2829. PubMed ID: 31162772
[TBL] [Abstract][Full Text] [Related]
13. Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial.
Lin YS; Yang H; Ding Y; Cheng YZ; Shi F; Tan J; Deng ZY; Chen ZD; Wang RF; Ji QH; Huang R; Li LF
Thyroid; 2021 Apr; 31(4):607-615. PubMed ID: 32907500
[No Abstract] [Full Text] [Related]
14. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population.
Ahmed M; Barbachano Y; Riddell A; Hickey J; Newbold KL; Viros A; Harrington KJ; Marais R; Nutting CM
Eur J Endocrinol; 2011 Aug; 165(2):315-22. PubMed ID: 21566072
[TBL] [Abstract][Full Text] [Related]
15. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer.
Schlumberger M; Jarzab B; Cabanillas ME; Robinson B; Pacini F; Ball DW; McCaffrey J; Newbold K; Allison R; Martins RG; Licitra LF; Shah MH; Bodenner D; Elisei R; Burmeister L; Funahashi Y; Ren M; O'Brien JP; Sherman SI
Clin Cancer Res; 2016 Jan; 22(1):44-53. PubMed ID: 26311725
[TBL] [Abstract][Full Text] [Related]
16. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
[TBL] [Abstract][Full Text] [Related]
17. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
Kurzrock R; Sherman SI; Ball DW; Forastiere AA; Cohen RB; Mehra R; Pfister DG; Cohen EE; Janisch L; Nauling F; Hong DS; Ng CS; Ye L; Gagel RF; Frye J; Müller T; Ratain MJ; Salgia R
J Clin Oncol; 2011 Jul; 29(19):2660-6. PubMed ID: 21606412
[TBL] [Abstract][Full Text] [Related]
18. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
Schneider TC; Abdulrahman RM; Corssmit EP; Morreau H; Smit JW; Kapiteijn E
Eur J Endocrinol; 2012 Nov; 167(5):643-50. PubMed ID: 22918300
[TBL] [Abstract][Full Text] [Related]
19. Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).
Capdevila J; Trigo JM; Aller J; Manzano JL; Adrián SG; Llopis CZ; Reig Ò; Bohn U; Cajal TRY; Duran-Poveda M; Astorga BG; López-Alfonso A; Martínez JM; Porras I; Reina JJ; Palacios N; Grande E; Cillán E; Matos I; Grau JJ
Eur J Endocrinol; 2017 Oct; 177(4):309-317. PubMed ID: 28687563
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
Gallo M; Michelon F; Castiglione A; Felicetti F; Viansone AA; Nervo A; Zichi C; Ciccone G; Piovesan A; Arvat E
Endocrine; 2015 Aug; 49(3):726-34. PubMed ID: 25414068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
